Published in N Engl J Med on June 25, 2009
Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology (2011) 5.06
Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology (2010) 2.40
A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology (2014) 2.00
Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci (2011) 1.70
The breathprints in patients with liver disease identify novel breath biomarkers in alcoholic hepatitis. Clin Gastroenterol Hepatol (2013) 1.67
Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: a critical role for E-selectin. Hepatology (2013) 1.58
Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut (2015) 1.54
Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol (2011) 1.52
Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut (2012) 1.51
Inflammation in alcoholic liver disease. Annu Rev Nutr (2012) 1.49
Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease. J Gastroenterol Hepatol (2012) 1.49
Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. J Gastroenterol Hepatol (2013) 1.35
Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology (2015) 1.32
Liver transplantation in alcoholic liver disease current status and controversies. World J Gastroenterol (2013) 1.30
Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol (2013) 1.25
Overview of lipid peroxidation products and hepatic protein modification in alcoholic liver disease. Chem Biol Interact (2011) 1.21
Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol (2011) 1.20
The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One (2012) 1.17
Alcoholic liver disease. World J Hepatol (2012) 1.16
Oxidative stress and redox signaling mechanisms of alcoholic liver disease: updated experimental and clinical evidence. J Dig Dis (2012) 1.14
Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology (2011) 1.07
CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut (2014) 1.06
Treatment of alcoholic liver disease. Therap Adv Gastroenterol (2011) 1.06
CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radic Biol Med (2013) 1.06
Trends in the management and burden of alcoholic liver disease. J Hepatol (2015) 1.05
Differential changes in MAP kinases, histone modifications, and liver injury in rats acutely treated with ethanol. Alcohol Clin Exp Res (2010) 1.03
Antioxidants as therapeutic agents for liver disease. Liver Int (2011) 1.02
Definition, epidemiology and magnitude of alcoholic hepatitis. World J Hepatol (2011) 0.99
Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis. Mayo Clin Proc (2011) 0.98
Oxidative Stress and the ER Stress Response in a Murine Model for Early-Stage Alcoholic Liver Disease. J Toxicol (2012) 0.97
Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials (2013) 0.95
Hepatocyte expression of the senescence marker p21 is linked to fibrosis and an adverse liver-related outcome in alcohol-related liver disease. PLoS One (2013) 0.95
Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLoS One (2011) 0.95
The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol (2011) 0.94
Molecular basis and current treatment for alcoholic liver disease. Int J Environ Res Public Health (2010) 0.94
Hepatoprotective and anti-fibrotic functions of interleukin-22: therapeutic potential for the treatment of alcoholic liver disease. J Gastroenterol Hepatol (2013) 0.94
Toll-like receptors in the pathogenesis of alcoholic liver disease. Gastroenterol Res Pract (2010) 0.93
Trends in Alcoholic Hepatitis-related Hospitalizations, Financial Burden, and Mortality in the United States. J Clin Gastroenterol (2015) 0.93
Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment. World J Gastroenterol (2014) 0.92
Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology (2016) 0.92
Opposing effects of prednisolone treatment on T/NKT cell- and hepatotoxin-mediated hepatitis in mice. Hepatology (2014) 0.92
Lipidomic changes in rat liver after long-term exposure to ethanol. Toxicol Appl Pharmacol (2011) 0.92
Experimental rat model for alcohol-induced osteonecrosis of the femoral head. Int J Exp Pathol (2013) 0.91
Susceptibility of L-FABP-/- mice to oxidative stress in early-stage alcoholic liver. J Lipid Res (2013) 0.91
Chronic ethanol ingestion induces oxidative kidney injury through taurine-inhibitable inflammation. Free Radic Biol Med (2014) 0.90
Acute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: an Italian position statement. World J Gastroenterol (2014) 0.90
Catechin suppresses an array of signalling molecules and modulates alcohol-induced endotoxin mediated liver injury in a rat model. PLoS One (2011) 0.90
Alcoholic and non-alcoholic steatohepatitis. Exp Mol Pathol (2014) 0.89
Serum metabolomic profiling in acute alcoholic hepatitis identifies multiple dysregulated pathways. PLoS One (2014) 0.89
Hyperbilirubinaemia and haemolytic anaemia in acute alcoholic hepatitis: there's oil in them thar veins. BMJ Case Rep (2014) 0.89
Caffeine protects against alcoholic liver injury by attenuating inflammatory response and oxidative stress. Inflamm Res (2010) 0.89
Fat-Specific Protein 27/CIDEC Promotes Development of Alcoholic Steatohepatitis in Mice and Humans. Gastroenterology (2015) 0.88
TLR2 and TLR9 contribute to alcohol-mediated liver injury through induction of CXCL1 and neutrophil infiltration. Am J Physiol Gastrointest Liver Physiol (2015) 0.88
KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol (2013) 0.87
Folate, alcohol, and liver disease. Mol Nutr Food Res (2012) 0.87
Inhibition of heat shock protein 90 alleviates steatosis and macrophage activation in murine alcoholic liver injury. J Hepatol (2014) 0.87
4-Hydroxynonenal in the pathogenesis and progression of human diseases. Curr Med Chem (2014) 0.87
Role of IRAK-M in alcohol induced liver injury. PLoS One (2013) 0.87
Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci (2012) 0.86
A meta-analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis. Can J Gastroenterol (2012) 0.85
Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol (2016) 0.85
Liver proteomics in progressive alcoholic steatosis. Toxicol Appl Pharmacol (2012) 0.85
Liver transplantation in acute alcoholic hepatitis: Current status and future development. World J Hepatol (2011) 0.84
Alcoholic hepatitis: Translational approaches to develop targeted therapies. Hepatology (2016) 0.84
Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol (2014) 0.83
Regulation of mitochondrial function by voltage dependent anion channels in ethanol metabolism and the Warburg effect. Biochim Biophys Acta (2011) 0.83
Role of Fn14 in acute alcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol (2014) 0.82
Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration. Cell Mol Immunol (2015) 0.82
Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Gastroenterol Hepatol (2016) 0.82
Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. BMC Gastroenterol (2015) 0.82
Role of Mitochondria in Alcoholic Liver Disease. Curr Pathobiol Rep (2013) 0.81
White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers. BMC Gastroenterol (2013) 0.81
Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians. World J Gastrointest Pharmacol Ther (2013) 0.81
Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination? World J Gastroenterol (2016) 0.80
Current Management of Alcoholic Hepatitis and Future Therapies. J Clin Transl Hepatol (2016) 0.80
Corticosteroids and pentoxifylline for the treatment of alcoholic hepatitis: Current status. World J Hepatol (2011) 0.80
Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol (2014) 0.80
Alcoholic liver disease: treatment. World J Gastroenterol (2014) 0.79
Increased plasma corticosterone contributes to the development of alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol (2013) 0.79
Granulocytapheresis for the treatment of severe alcoholic hepatitis: a case series and literature review. Dig Dis Sci (2013) 0.79
Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights. J Gastroenterol (2016) 0.79
Diagnosis of alcoholic liver disease. World J Gastroenterol (2014) 0.79
Is liver biopsy necessary in the management of alcoholic hepatitis? World J Gastroenterol (2013) 0.79
Severe alcoholic hepatitis-current concepts, diagnosis and treatment options. World J Hepatol (2014) 0.79
Therapeutic potential of interleukin 1 inhibitors in the treatment of alcoholic liver disease. Hepatology (2013) 0.78
SIRS at Admission Is a Predictor of AKI Development and Mortality in Hospitalized Patients with Severe Alcoholic Hepatitis. Dig Dis Sci (2015) 0.78
Alcoholic hepatitis: current management. Dig Dis Sci (2014) 0.78
Immune dysfunction in acute alcoholic hepatitis. World J Gastroenterol (2015) 0.78
Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines. Alcohol Clin Exp Res (2014) 0.78
Focus on alcoholic liver disease: from nosography to treatment. World J Gastroenterol (2014) 0.78
Pharmacotherapy of acute alcoholic hepatitis in clinical practice. World J Gastroenterol (2014) 0.78
Ecklonia cava Polyphenol Has a Protective Effect against Ethanol-Induced Liver Injury in a Cyclic AMP-Dependent Manner. Mar Drugs (2015) 0.78
Update on Alcoholic Hepatitis. Biomolecules (2015) 0.78
The Role of Innate Immunity in Alcoholic Liver Disease. Alcohol Res (2015) 0.78
Myeloperoxidase formation of PAF receptor ligands induces PAF receptor-dependent kidney injury during ethanol consumption. Free Radic Biol Med (2015) 0.77
Diagnosis and Treatment of Alcoholic Hepatitis: A Systematic Review. Alcohol Clin Exp Res (2016) 0.77
Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease. Hepatology (2016) 0.77
Increased Sensitivity to Binge Alcohol-Induced Gut Leakiness and Inflammatory Liver Disease in HIV Transgenic Rats. PLoS One (2015) 0.77
Alcoholic hepatitis and concomitant hepatitis C virus infection. World J Gastroenterol (2014) 0.77
ChIP-seq in steatohepatitis and normal liver tissue identifies candidate disease mechanisms related to progression to cancer. BMC Med Genomics (2013) 0.77
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology (2007) 3.75
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology (2014) 3.30
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology (2004) 3.04
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology (2007) 2.20
Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology (2011) 2.14
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: a modeling approach. Hepatology (2014) 2.05
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol (2010) 2.02
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 1.94
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology (2012) 1.89
Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut (2010) 1.83
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol (2011) 1.73
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol (2010) 1.68
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology (2008) 1.66
Epidemiology of alcoholic liver disease. Semin Liver Dis (2004) 1.66
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. J Hepatol (2013) 1.61
Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol (2012) 1.55
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology (2010) 1.52
Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology (2009) 1.50
The immunology of fibrogenesis in alcoholic liver disease. Arch Pathol Lab Med (2004) 1.41
Patients with acute liver failure listed for superurgent liver transplantation in France: reevaluation of the Clichy-Villejuif criteria. Liver Transpl (2015) 1.38
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol (2006) 1.38
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology (2005) 1.33
Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology (2002) 1.27
Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol (2007) 1.26
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol (2006) 1.18
Hepatitis C virus therapy to date. Antivir Ther (2008) 1.16
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13
Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. Glycobiology (2005) 1.13
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology (2012) 1.12
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology (2009) 1.08
Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol (2010) 1.08
Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding. Hepatology (2015) 1.08
Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol (2008) 1.07
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol (2012) 1.05
The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol (2008) 1.04
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One (2011) 1.04
Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med (2013) 1.01
Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? J Clin Gastroenterol (2008) 0.99
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 0.98
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology (2011) 0.98
Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol (2002) 0.97
Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology (2011) 0.95
NOD2: a potential target for regulating liver injury. Lab Invest (2008) 0.95
Mesenteric adenitis and portal vein thrombosis due to Fusobacterium nucleatum. Eur J Gastroenterol Hepatol (2004) 0.95
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS One (2012) 0.94
Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol (2009) 0.94
Liver disease in alcohol and hepatitis C. Best Pract Res Clin Gastroenterol (2003) 0.94
Neutrophil migration during liver injury is under nucleotide-binding oligomerization domain 1 control. Gastroenterology (2009) 0.92
Alcoholic liver disease - Hepatocellular carcinoma transformation. J Gastrointest Oncol (2012) 0.92
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Gastroenterology (2011) 0.92
Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg (2014) 0.92
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology (2008) 0.91
Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol (2004) 0.91
Prothrombin index decrease: a useful and reliable marker of extensive fibrosis? Eur J Gastroenterol Hepatol (2002) 0.90
Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. Liver Int (2014) 0.90
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol (2011) 0.89
Usefulness of routine analysis of ascitic fluid at the time of therapeutic paracentesis in asymptomatic outpatients. Results of a multicenter prospective study. Gastroenterol Clin Biol (2005) 0.89
Relevance of the ISGLS definition of posthepatectomy liver failure in early prediction of poor outcome after liver resection: study on 680 hepatectomies. Ann Surg (2014) 0.88
Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol (2009) 0.88
Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. J Hepatol (2002) 0.88
micro-Opioid receptor activation prevents acute hepatic inflammation and cell death. Gut (2007) 0.86
Impact of impaired aerobic capacity on liver transplant candidates. Transplantation (2008) 0.86
Assessing bone status in patients awaiting liver transplantation. Joint Bone Spine (2011) 0.84
Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis. J Hepatol (2012) 0.83
Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. Stat Methods Med Res (2008) 0.83
Brief report: genetics of alcoholic cirrhosis-GenomALC multinational study. Alcohol Clin Exp Res (2015) 0.83
Peroxisome proliferator-activated receptors in HBV-related infection. PPAR Res (2009) 0.82
Bariatric surgery for curing NASH in the morbidly obese? J Hepatol (2013) 0.82
Extensive portal vein thrombosis related to abdominal trauma. Gastroenterol Clin Biol (2006) 0.81
Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: a case-control study. Liver Transpl (2007) 0.81